Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non-controlling Interest
Beginning Balance, Amount at Sep. 30, 2018	$ 95,241	$ 181	$ 582,903	$ (22)	$ (487,266)	$ (555)
Beginning Balance, Shares at Sep. 30, 2018		88,505,000
Stock-based compensation	12,393		12,393
Exercise of stock options, Amount	8,276	$ 2	8,274
Exercise of stock options, Shares		1,543,000
Common stock - restricted stock units vesting, Amount		$ 2	(2)
Common stock - restricted stock units vesting, Shares		2,197,000
Common stock - issued for cash, Amount	60,521	$ 3	60,518
Common stock - issued for cash, Shares		3,261,000
Foreign currency translation adjustments	(370)			(370)
Net income (loss)	67,975				67,975
Ending Balance, Amount at Sep. 30, 2019	244,036	$ 188	664,086	(392)	(419,291)	(555)
Ending Balance, Shares at Sep. 30, 2019		95,506,000
Stock-based compensation	43,383		43,383
Exercise of stock options, Amount	7,469	$ 1	7,468
Exercise of stock options, Shares		1,111,000
Common stock - restricted stock units vesting, Amount		$ 1	(1)
Common stock - restricted stock units vesting, Shares		1,159,000
Common stock - issued for cash, Amount	250,479	$ 5	250,474
Common stock - issued for cash, Shares		4,600,000
Foreign currency translation adjustments	410			410
Deconsolidation of Ablaris Therapeutics, Inc.	555					$ 555
Net income (loss)	(84,553)				(84,553)
Ending Balance, Amount at Sep. 30, 2020	461,779	$ 195	965,410	18	(503,844)
Ending Balance, Shares at Sep. 30, 2020		102,376,000
Stock-based compensation	76,673		76,673
Exercise of stock options, Amount	$ 11,305	$ 1	11,304
Exercise of stock options, Shares	1,051,344	1,052,000
Common stock - restricted stock units vesting, Amount		$ 1	(1)
Common stock - restricted stock units vesting, Shares		899,000
Foreign currency translation adjustments	$ (87)			(87)
Net income (loss)	(140,848)				(140,848)
Ending Balance, Amount at Sep. 30, 2021	$ 408,822	$ 197	$ 1,053,386	$ (69)	$ (644,692)
Ending Balance, Shares at Sep. 30, 2021		104,327,000